4.5 Article

No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease

Journal

NEUROBIOLOGY OF AGING
Volume 74, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2018.09.022

Keywords

Parkinson's disease; Age at onset; DNM3

Funding

  1. South-Eastern Norway Regional Health Authority
  2. Research Council of Norway
  3. Norwegian Health Association
  4. Mayo Clinic Center for Individualized Medicine
  5. Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation)
  6. Mayo Clinic Neuroscience Focused Research Team (James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida)
  7. Sol Goldman Charitable Trust
  8. NINDS [R01 NS078086, NS072187]
  9. Department of Defense award [W81XWH-16-PRMRP-IIRA]
  10. Michael J. Fox Foundation
  11. AbbVie
  12. Avid Radiopharmaceuticals
  13. Biogen
  14. BioLegend
  15. Bristol-Myers Squibb
  16. GE Healthcare
  17. Genentech
  18. GlaxoSmithKline
  19. Lilly
  20. Lundbeck
  21. Merck
  22. Meso Scale Discovery
  23. Pfizer
  24. Piramal
  25. Roche
  26. Sanofi Genzyme
  27. Servier
  28. Takeda
  29. Teva
  30. UCB
  31. Michael J. Fox Foundation for Parkinson's Research

Ask authors/readers for more resources

Parkinson's disease (PD) is a disorder with highly variable clinical phenotype. The identification of genetic variants modifying age at onset and other traits is of great interest because it may provide insight into disease mechanisms and potential therapeutic targets. A variant in the DNM3 gene (rs2421947) has been reported as a genetic modifier of age at onset in LRRK2-associated PD. To test the possible effect of genetic variation in DNM3 on age at onset in idiopathic PD, we examined rs2421947 in a total of 5918 patients with PD from seven data sets. We also assessed the potential effect of all common variants in the DNM3 locus. There was no significant association between rs2421947 and age at onset in any of the individual studies. Meta-analysis of the seven studies was nonsignificant and the between-study heterogeneity was minimal. No other common variants within the DNM3 locus affected age at onset. In conclusion, we find no evidence of an association between DNM3 variants and age at onset in idiopathic PD. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available